Routes of
administration By mouth, intravenous Legal status Investigational PubChem CID 11610526 Molar mass 377.36 g/mol | ATC code none CAS Number 439239-90-4 IUPHAR/BPS 3928 | |
 | ||
How to pronounce lasmiditan
Lasmiditan (COL-144) is an investigational drug for the treatment of acute migraine. It is being developed by Eli Lilly and is in phase III clinical trials. It is a first-in-class "neurally acting anti-migraine agent" ditan.
Contents
Mechanism of action
Lasmiditan is a serotonin receptor agonist that, like the unsuccessful LY-334,370, selectively binds to the 5-HT1F receptor subtype. A number of triptans have been shown to act on this subtype as well, but only after their affinity for 5-HT1B and 5-HT1D has been made responsible for their anti-migraine activity. The lack of affinity for these receptors might result in fewer side effects related to vasoconstriction compared to triptans in susceptible patients, such as those with ischemic heart disease, Raynaud's phenomenon or after a myocardial infarction, although a 1998 review has found such side-effects to rarely occur in patients taking triptans.
Discovery and development
Lasmiditan was discovered by Eli Lilly and Company and was out-licensed to CoLucid Pharmaceuticals in 2006, until CoLucid was bought by Eli Lilly in 2017 to reacquire the drug. The drug is protected by patents until 2031.
Phase II clinical trials for dose finding purposes were completed in 2007 for an intravenous form and in early 2010 for an oral form. Two separate Phase III clinical trials for the oral version are currently ongoing under special protocol agreements with the US Food and Drug Administration (FDA). Eli Lilly has stated that they intend to submit a new drug application to the FDA in early 2018.
As of 2017, three phase III clinical trials have been completed or are in progress. The SPARTAN trial compares placebo with 50, 100, and 200 mg of lasmiditan. SAMURAI compared placebo with 100 and 200 mg doses of lasmidatin. In 2016, CoLucid announced that the trial had met it's primary and secondary endpoints of patients being pain-free two hours after dosing. GLADIATOR is an open-label study comparing 100 and 200 mg doses of lasmidatin in patients that received the drug as part of a prior trial.